within Pharmacolibrary.Drugs.ATC.G;

model G04BD11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.52,
    Cl             = 7.0 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 8 / 1000000,
    adminCount     = 1,
    Vd             = 0.169,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.025,
    Tlag           = 13.8
  );

  annotation(Documentation(
    info ="<html><body><p>Fesoterodine is an antimuscarinic agent used for the treatment of overactive bladder with symptoms of urinary frequency, urgency, and urge incontinence. It is an approved oral medication active as a prodrug, rapidly converted to its active metabolite 5-hydroxymethyl tolterodine (5-HMT).</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters of fesoterodine (as its active metabolite 5-HMT) were characterized in healthy adult subjects (male and female, age 18-55) after administration of the recommended 8 mg oral dose in the fasted state.</p><h4>References</h4><ol><li><p>Shin, D, et al., &amp; Yu, KS (2012). Multiple-dose pharmacokinetics of fesoterodine sustained-release in healthy Korean volunteers. <i>International journal of clinical pharmacology and therapeutics</i> 50(10) 722–728. DOI:<a href=&quot;https://doi.org/10.5414/CP201708&quot;>10.5414/CP201708</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22853865/&quot;>https://pubmed.ncbi.nlm.nih.gov/22853865</a></p></li><li><p>Malhotra, B, et al., &amp; Wood, N (2009). Evaluation of drug-drug interactions with fesoterodine. <i>European journal of clinical pharmacology</i> 65(6) 551–560. DOI:<a href=&quot;https://doi.org/10.1007/s00228-009-0648-1&quot;>10.1007/s00228-009-0648-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19347334/&quot;>https://pubmed.ncbi.nlm.nih.gov/19347334</a></p></li><li><p>Malhotra, BK, et al., &amp; Sachse, R (2009). Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. <i>International journal of clinical pharmacology and therapeutics</i> 47(9) 570–578. DOI:<a href=&quot;https://doi.org/10.5414/cpp47570&quot;>10.5414/cpp47570</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19761716/&quot;>https://pubmed.ncbi.nlm.nih.gov/19761716</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end G04BD11;
